Regulatory Rejection and Market Impact
On November 20, 2026, the US Food and Drug Administration (FDA) formally declined to approve Capricor Therapeutics’ experimental cell therapy, deramiocel, intended for the treatment of Duchenne muscular dystrophy (DMD). The regulatory rejection, which followed a period of intense scrutiny, caused shares of the biotech firm to plummet by 77% in extended trading sessions, according to reporting by WinCountry. The market reaction underscores the high stakes surrounding the company’s lead experimental asset, which investors had hoped would provide a pathway to commercialization.
The decision represents a major setback for Capricor, which had attempted to salvage the application by narrowing the treatment’s scope to the preservation of upper-limb function in patients. The company had submitted an amended application in August 2026, incorporating 24-month data from a late-stage clinical study to support its case, yet this effort ultimately failed to satisfy federal regulators.
Data Integrity and Protocol Violations
In its formal rejection notice, the FDA highlighted significant concerns regarding the integrity of the data submitted by the company. The agency cited specific, unauthorized modifications to the trial’s statistical analysis plan that occurred after the study had already commenced. Furthermore, the FDA identified systemic violations of rules designed to maintain double-blind conditions—procedures intended to prevent both patients and researchers from knowing which participants received the active treatment versus the placebo.
The FDA concluded that these systemic issues “compromise the reliability of the study data,” rendering the results “not considered reliable or interpretable” as evidence of clinical efficacy. Additionally, the regulator noted that the therapy failed to meet the primary endpoints defined in the study protocol. As STAT reported, the clinical trials failed to demonstrate that deramiocel could effectively stave off heart failure or preserve muscle function in the arms of the target patient population, which includes teenagers and young men who have already lost the ability to walk.
Context and Clinical Stakes
Duchenne muscular dystrophy is a fatal genetic condition characterized by progressive muscle weakness, heart complications, and premature death, primarily affecting boys. Given the severity of the disease and the limited number of existing treatment options, the regulatory process has been particularly complex. This latest rejection follows a July 2026 advisory vote, where FDA experts voted nine-to-three against the evidence presented at that time regarding the drug’s effectiveness in treating Duchenne-related heart disease. Capricor did not immediately respond to requests for comment regarding the future of its lead experimental asset or potential next steps for the company’s clinical pipeline.
The broader implications for the biotech sector remain significant, as the FDA continues to enforce stringent requirements for trial data integrity in rare disease research. For patients and families affected by Duchenne, the rejection highlights the ongoing challenge of developing viable therapies for conditions where historical trial data has often been subject to intense scrutiny. The company now faces a difficult path forward as it attempts to address the regulators’ findings, although it has provided no immediate guidance on whether it intends to appeal the decision or initiate new clinical studies to satisfy the FDA’s rigorous standards.

